Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Poll|October 15, 2019
Mini Quiz: Antipsychotic Polypharmacy
Author(s)Jose M. Rubio, MD, PhD
Listen
0:00 / 0:00
Key Takeaways
- Randomized controlled trials assess polypharmacy's efficacy in managing psychoses' diverse symptom domains, comparing it to monotherapy approaches.
- The trials aim to optimize treatment strategies by evaluating the benefits and risks of combining multiple medications.
Which treatments have proven to be efficacious in meta-analyses as augmentation of clozapine in reducing positive symptoms of schizophrenia? The answer might surprise you.
Advertisement
Hundreds of randomized controlled trials have been conducted to test the efficacy of the multiple forms of polypharmacy in various symptom domains of psychoses.
Which of the following has proven to be efficacious in meta-analyses as augmentation of clozapine in reducing positive symptoms?
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
3
How a Learning Health Network Could Transform Bipolar Disorder Treatment: A Conversation With Andrew Nierenberg, MD
4
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
5